stuartlpbi | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Feeds:: Posts; Comments

About: Stuart Cantor

Website: http://stuartlpbi.wordpress.com
Details: I have a Ph.D. in pharmaceutical sciences and my expertise is in solid oral dosage formulation development and controlled-release technologies. I also have a deep background in intellectual property in the areas of chemistry, pharma, medical device, and biotech.

Posts by Stuart Cantor:

February 8, 2016 Bio-MEMS Technologies: Devices, Tissue Engineering & Drug Delivery, Presentation by Stuart Cantor, Ph.D. on 2/4/16

Follow Blog via Email

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,044 other followers

Email Address:
Recent Posts
- COVID-19 T-cell immune response map, immunoSEQ T-MAP COVID for research of T-cell response to SARS-CoV-2 infection November 20, 2020
- Nanoparticles can turn off genes in bone marrow cells November 19, 2020
- The complication of Pfizer’s Vaccine Distribution’s Plan November 19, 2020
- Regeneron’s new antibody cocktail drug, REGN-COV2 November 18, 2020
- McKinsey experts on COVID-19: Implications for business: Executive Briefing November 18, 2020
- Leveraging Clinical Narrative Text at Scale: Applying Natural Language Processing to Understand the Patient Care Experience @NIH.gov November 18, 2020
- re:Invent 2020 – Virtual 3 weeks Conference, Nov. 30 – Dec. 18, 2020: How Healthcare & Life Sciences leaders are using AWS to transform their businesses and innovate on behalf of their customers. November 18, 2020
- Data Architecture for Blockchain Deployment of Digital Assets: LPBI IP Asset Classes I,II,III November 16, 2020
- First-ever living 3D-printed aneurysm November 15, 2020
- Deep Medicine: How Artificial Intelligence Can Make Health Care Human Again November 11, 2020
Archives
Archives
Categories
Categories
Meta